Mandate

Vinge advises Ingrid Capacity in its partnership with SEB Nordic Energy’s portfolio company Locus Energy

September 03, 2024 M&A Banking and Finance

Vinge has advised Ingrid Capacity in connection with the entering into a strategic partnership with Locus Energy, a leading Nordic energy infrastructure company owned by SEB Asset Management's fund SEB Nordic Energy.

The partnership will enable the construction of 13 new large-scale battery energy storage systems across southern Sweden, adding an additional 196 MW of flexible capacity to the national grid in price areas SE3 and SE4. The investment is the second largest of its kind in Sweden and the Nordics.

Ingrid Capacity’s business model entails the construction of large-scale battery energy storage facilities in Europe. I Sweden the batteries will e.g. be used to help Svenska Kraftnät and regional and local electricity network companies to secure the energy supply. Ingrid Capacity was founded in 2022, had a revenue of ca MSEK 117 in 2023, and has 50 employees.

The transaction is subject to applicable regulatory approvals.

Vinge's team consisted primarily of Carl Sander, Jonas Bergström, Vilhelm Rondahl, and Matilda Hamner (M&A), Christoffer Thalin and Jonatan Karlsson (Energy), and Helena Göransson and Jolinn Uhlin (Banking & Finance).

For more information, please click here.

Related

Vinge advises Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun

Vinge is advising Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun from Dalafast. The acquisition comprises four properties with a total of 23,200 square metres of retail space, which together constitute Tallen’s largest retail area.
November 11, 2026

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026